Analysts Adjust Price Targets for Intuitive Surgical Following Q3 Results

Following Intuitive Surgical's Q3 2026 earnings report, analysts have revised their price targets for the company's stock. Raymond James adjusted its target to $480 from $483, RBC Capital lowered its target to $550 from $575 while maintaining an Outperform rating, and Mizuho Securities revised its target to $400 from $415. These changes come after the company announced a $450 million antitrust settlement and a narrowed growth outlook for its da Vinci surgical systems.